Search
Tianeptine
go.drugbank.com/drugs/DB09289InvestigationalTianeptine is a drug used primarily in the treatment of major depressive disorder and has been studied in the treatment of irritable bowel syndrome (IBS) [A31983]. … Tianeptine was discovered and patented by The French Society of Medical Research in the 1960s [L2946].
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexBamlanivimab
go.drugbank.com/drugs/DB15718ApprovedInvestigational[L15316, L15321] Under the EUA granted in February 2021, bamlanivimab is used in combination with [etesevimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk … Bamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19.
Carbon monoxide
go.drugbank.com/drugs/DB11588ApprovedInvestigationalA December 2001 report from the European Commission's Scientific Committee on Food concluded that the gas did not pose a risk provided that food was maintained adequately cold during storage and transport … It is toxic to hemoglobin utilizing animals (including humans), when encountered in concentrations above about 35 ppm, although it is also formed in normal animal metabolism in low quantities, and is thought
Synonyms: carbon(II) oxide, COMixtures: Co-NE-O2-N2 Mixture, Co-HE-O2-N2 MixtureSonidegib
go.drugbank.com/drugs/DB09143ApprovedInvestigationalSonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesSynonyms: N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridin-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamideBezisterim
go.drugbank.com/drugs/DB05212InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTrospium
go.drugbank.com/drugs/DB00209ApprovedInvestigational[L6208] Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007.[L6211] … Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably.
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsInternational brands: Tropez ODDeutivacaftor
go.drugbank.com/drugs/DB15141ApprovedInvestigationalIt is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis. … [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsSynonyms: D9-IvacaftorBenserazide
go.drugbank.com/drugs/DB12783ApprovedInvestigationalWhen levodopa is used by itself as a therapy for treating Parkinson's disease, its ubiquitous metabolism into dopamine is responsible for a resultant increase in the levels of circulating dopamine in the … combination in the form of levodopa and carbidopa.
Mixtures: MADOPAR®, MADOPAR®Categories: Aromatic L-amino Acid Decarboxylase InhibitorsCilostazol
go.drugbank.com/drugs/DB01166ApprovedInvestigationalCilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia … It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
Categories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 SubstratesSynonyms: 3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinoneInebilizumab
go.drugbank.com/drugs/DB12530ApprovedInvestigational[L14315] Given its mechanism of action and good safety profile, it may prove useful in the treatment of other conditions linked to autoimmune antibody production or B-cell malignancies. … Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD.
Products: UPLIZNA®